Mivi Neuroscience, an Eden Praire, Minn.-based medical device company focused on improving clinical outcomes for ischemic stroke patients, closed a $35m Series B funding in new money plus the conversion of previously issued convertible notes.
The round was led by a major multinational med-tech company and included participation from new investors Perceptive Advisors, Deerfield Management and Aphelion / Cardeation Capital as well as existing investors including Concord Health Partners.
This major investment will be used to fund the clinical trials and subsequent commercialization of Mivi’s two flagship products, the Q™ Aspiration System and the DAISe™ Thrombectomy System, as well as expanding the company’s commercial operations outside the United States and driving the development of several innovative devices designed to support and enhance its products.
Led by Bob Colloton, CEO, Mivi Neuroscience focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Its innovative product portfolio provides physicians with unique devices designed to improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients.